These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19622698)

  • 1. The role of melatonin in sleep disturbances in end-stage Huntington's disease.
    Alders J; Smits M; Kremer B; Naarding P
    J Neuropsychiatry Clin Neurosci; 2009; 21(2):226-7. PubMed ID: 19622698
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed onset of the diurnal melatonin rise in patients with Huntington's disease.
    Aziz NA; Pijl H; Frölich M; Schröder-van der Elst JP; van der Bent C; Roelfsema F; Roos RA
    J Neurol; 2009 Dec; 256(12):1961-5. PubMed ID: 19562249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma melatonin is reduced in Huntington's disease.
    Kalliolia E; Silajdžić E; Nambron R; Hill NR; Doshi A; Frost C; Watt H; Hindmarsh P; Björkqvist M; Warner TT
    Mov Disord; 2014 Oct; 29(12):1511-5. PubMed ID: 25164424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep deficits but no metabolic deficits in premanifest Huntington's disease.
    Lazar AS; Panin F; Goodman AO; Lazic SE; Lazar ZI; Mason SL; Rogers L; Murgatroyd PR; Watson LP; Singh P; Borowsky B; Shneerson JM; Barker RA
    Ann Neurol; 2015 Oct; 78(4):630-48. PubMed ID: 26224419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal secretion of melatonin and cortisol in relation to sleep disturbances in children with Williams syndrome.
    Sniecinska-Cooper AM; Iles RK; Butler SA; Jones H; Bayford R; Dimitriou D
    Sleep Med; 2015 Jan; 16(1):94-100. PubMed ID: 25441742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications.
    Aziz NA; Swaab DF; Pijl H; Roos RA
    Rev Neurosci; 2007; 18(3-4):223-51. PubMed ID: 18019608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep disturbances and severity of Huntington's disease.
    Hansotia P; Wall R; Berendes J
    Neurology; 1985 Nov; 35(11):1672-4. PubMed ID: 2932657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disorders of nocturnal sleep in Huntington chorea].
    Iakhno NN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):340-6. PubMed ID: 2986395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder.
    Paavonen EJ; Nieminen-von Wendt T; Vanhala R; Aronen ET; von Wendt L
    J Child Adolesc Psychopharmacol; 2003; 13(1):83-95. PubMed ID: 12804129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative care for people with late-stage Huntington's disease.
    Moskowitz CB; Marder K
    Neurol Clin; 2001 Nov; 19(4):849-65. PubMed ID: 11854103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease.
    Chakraborty J; Nthenge-Ngumbau DN; Rajamma U; Mohanakumar KP
    Behav Brain Res; 2014 May; 264():91-104. PubMed ID: 24509309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia.
    Escribano BM; Colín-González AL; Santamaría A; Túnez I
    CNS Neurol Disord Drug Targets; 2014; 13(6):1096-119. PubMed ID: 25106623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease.
    Aziz NA; Anguelova GV; Marinus J; Lammers GJ; Roos RA
    Parkinsonism Relat Disord; 2010 Jun; 16(5):345-50. PubMed ID: 20236854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin.
    Antunes Wilhelm E; Ricardo Jesse C; Folharini Bortolatto C; Wayne Nogueira C
    Eur J Pharmacol; 2013 Feb; 701(1-3):65-72. PubMed ID: 23340221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin and mitochondrial dysfunction in the central nervous system.
    Cardinali DP; Pagano ES; Scacchi Bernasconi PA; Reynoso R; Scacchi P
    Horm Behav; 2013 Feb; 63(2):322-30. PubMed ID: 22391273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocretin-1 and secondary signs in Huntington's disease.
    Roos RA; Aziz NA
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S387-90. PubMed ID: 18267269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep characteristics of children with Williams syndrome in relation to saliva melatonin and cortisol.
    Kawada T
    Sleep Med; 2015 Sep; 16(9):1176. PubMed ID: 26141009
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting cerebrovascular impairments in Huntington's disease: a novel treatment perspective.
    St-Amour I; Aubé B; Rieux M; Cicchetti F
    Neurodegener Dis Manag; 2015 Oct; 5(5):389-93. PubMed ID: 26517444
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to the letter "Sleep characteristics of children with Williams syndrome in relation to saliva melatonin and cortisol".
    Sniecinska-Cooper AM; Iles RK; Butler SA; Jones H; Bayford R; Dimitriou D
    Sleep Med; 2015 Sep; 16(9):1177. PubMed ID: 26141005
    [No Abstract]   [Full Text] [Related]  

  • 20. [Melatonin. Physiology and clinical applications].
    Cardinali DP
    Vertex; 2007; 18(74):288-93. PubMed ID: 18219402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.